Rare disease focus Kedrion Biopharma US is a global leader in plasma-derived therapies with a mission around rare and ultra-rare diseases, presenting a strong opportunity to upsell to specialty clinics, patient advocacy groups, and rare disease networks seeking high-quality plasma-derived treatments.

US market expansion Recent launch of QIVIGY in the U.S. and nationwide distribution indicates an active growth strategy in the domestic market, suggesting opportunities to partner with hospitals, infusion centers, and wholesalers to broaden access.

Integrated supply potential Kedrion emphasizes an integrated international manufacturing network and full product lifecycle from plasma collection to distribution, which could appeal to health systems seeking reliable, end-to-end supply and consistent product availability.

Strategic partnerships Recent collaborations with Local Infusion and involvement in NY Tech Week and AI healthcare innovation signals openness to co-development, digital health tools, and patient-centric programs that can be leveraged for joint value-based initiatives and market education.

Clinical evidence focus Active participation in ISTH events and ongoing rare disease evidence generation create fodder for conversations around clinical outcomes, real-world data collaborations, and payer-focused value propositions to support formulary and coverage decisions.